Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients

NCT01578213 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

112

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: Imatinib mesylate

Sponsor

University of Milano Bicocca